Liposomal drug formulations for treatment of hematological malignancies

References

• Ghasemi K, Vaseghi G, Mansourian M. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: a network meta-analysis of metastatic breast cancer. J Oncol Pharm Pract. 2021 Mar;27(2):414–427. doi: 10.1177/1078155220965674
   PubMed Web of Science ®Google Scholar
• Ansari L, Shiehzadeh F, Taherzadeh Z, et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther. 2017 May;24(5):189–193. doi: 10.1038/cgt.2017.9
   PubMed Web of Science ®Google Scholar
• Petersen GH, Alzghari SK, Chee W, et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release. 2016 Jun 28;232:255–264. doi: 10.1016/j.jconrel.2016.04.028
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892–3901. doi: 10.1200/JCO.2006.10.5460
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050–2056. doi: 10.1002/cncr.30026
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006 Feb 15;106(4):848–858. doi: 10.1002/cncr.21662
   PubMed Web of Science ®Google Scholar
• Schroeder MA, Fiala MA, Huselton E, et al. A phase I/II trial of Carfilzomib, pegylated liposomal doxorubicin, and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2019 Jul 1;25(13):3776–3783. doi: 10.1158/1078-0432.CCR-18-1909
   PubMed Web of Science ®Google Scholar
• Cohen A, Spektor TM, Stampleman L, et al. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. Br J Haematol. 2018 Jan;180(1):60–70. doi: 10.1111/bjh.14992
   PubMed Web of Science ®Google Scholar
• Becker PS, Gooley TA, Green DJ, et al. A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. Blood Cancer J. 2016 May 13;6(5):e422. doi: 10.1038/bcj.2016.31
   PubMedGoogle Scholar
• Baz RC, Shain KH, Hussein MA, et al. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62–67. doi: 10.1002/ajh.23587
   PubMed Web of Science ®Google Scholar
• Sher T, Ailawadhi S, Miller KC, et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul;154(1):104–110. doi: 10.1111/j.1365-2141.2011.08703.x
   PubMed Web of Science ®Google Scholar
• Tomlinson BK, Tuscano JM, Abedi M, et al. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):E291–e294. doi: 10.1002/ajh.25605
   PubMed Web of Science ®Google Scholar
• Yao H, Zhang C, Tan X, et al. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia. Cancer Med. 2023 Jun;12(11):12377–12387. doi: 10.1002/cam4.5938
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009 Jan;33(1):129–139. doi: 10.1016/j.leukres.2008.06.028
   PubMed Web of Science ®Google Scholar
• Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011 Jul;39(7):741–750. doi: 10.1016/j.exphem.2011.04.001
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684–2692. doi: 10.1200/JCO.2017.77.6112
   PubMed Web of Science ®Google Scholar
• Cortes JE, Lin TL, Uy GL, et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 Jul 13;14(1):110. doi: 10.1186/s13045-021-01119-w
   PubMed Web of Science ®Google Scholar
• Benitez LL, Perissinotti AJ, Rausch CR, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Sep;62(9):2184–2192. doi: 10.1080/10428194.2021.1907378
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian cancer drug therapy working group [arbeitsgemeinschaft medikamentöse tumortherapie AGMT](NHL-14). Eur J Cancer. 2016 May;58:112–121. doi: 10.1016/j.ejca.2016.02.004
   PubMed Web of Science ®Google Scholar
• Sancho JM, Fernández-Alvarez R, Gual-Capllonch F, et al. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 2021 Feb;10(4):1314–1326. doi: 10.1002/cam4.3730
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol. 2008 Dec;143(5):681–689. doi: 10.1111/j.1365-2141.2008.07400.x
   PubMed Web of Science ®Google Scholar
• Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999 Oct;17(10):3110–3116. doi: 10.1200/JCO.1999.17.10.3110
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome–negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20;31(6):676–683. doi: 10.1200/JCO.2012.46.2309
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766–1770. doi: 10.1182/blood.2021014401
   PubMed Web of Science ®Google Scholar
• Gyöngyösi M, Lukovic D, Zlabinger K, et al. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovasc Res. 2020 Apr 1;116(5):970–982. doi: 10.1093/cvr/cvz192
   PubMed Web of Science ®Google Scholar